spacer
home > ebr > Winter 2008
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2008
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR
   
Text
PDF
bullet
BioFinance and Management
Maximising press coverage of anything from new product launches, to research, to company restructure is a continuous challenge for biopharmaceutical companies. Michael Willett at Bruker BioSciences outlines the various options available to get your story In the Flow  
view
download pdf
Robin Ng and Stephanie Finnegan at Goodwin Biotechnology, Inc give their advice on the benefits of attracting high-flying graduates to new roles, and the tactics involved in Winning the War of competitive recruitment within the biopharma industry  
view
download pdf
Having The Last Word in the press is a key aim for most biopharmaceutical companies. Sue Charles of College Hill examines the value of communications as a key business investment  
view
download pdf
The up-to-the-minute information, research and opportunity for discussion that the internet can provide has revolutionised the world of scientific communications, argues Sabine Duntze at b3c communications in Weaving a New Web  
view
download pdf
bullet
BioBusiness Development
Dr Achim Plum and Dr Oliver Schacht at Epigenomics AG investigate the lucrative potential of companies working together on drug development, and suggest that effective partnering allows even the smallest biotechs to have a chance at Playing in the Big Leagues  
view
download pdf
One way to get ahead of the biopharma game is through exploiting the full potential of networking within the industry; Dr Kate Rowley at Nexxus, the West of Scotland Bioscience Network, outlines its role in Partnering: the Modern Day Paradigm for Progression  
view
download pdf
The challenge of transcending national borders is one that most biopharmaceutical companies face at some stage during the drug development process. Dan Zabrowski at Roche persuades that Pursuing Partnerships is the recipe for pioneering progression  
view
download pdf
Martin Dittmer at Rockwell Automation considers The Path to Paperless Production, and concludes that electronic batch recording can transform every aspect of pharmaceutical manufacturing – from innovation to the marketplace  
view
download pdf
bullet
BioResearch and Innovation
New therapeutic paradigms rarely cause a stir comparable to that of RNAi – everyone from the new generation of biotech entrepreneurs to Wall Street has taken notice, even before its first market approval. Drug development consultant Emile Bellott investigates whether or not this excitement is justified, in A Glass Half-Full  
view
download pdf
Andreas Busjahn at HealthTwiSt predicts a potentially crucial development for biopharmaceutical R&D in Double Take, asserting that the application of molecular genetics may give the fast-diminishing use of twin studies a second wind  
view
download pdf
Advances in nanotechnology have opened up the possibility of a new era of personalised oncology, thereby providing cancer patients with more accurate diagnoses and more effective treatment. In This Time it’s Personal, Sylvia M Findlay at Frost & Sullivan assesses the communication difficulties facing this fresh approach  
view
download pdf
bullet
Discovery Technology
With an ever-increasing demand for adapted proteins, taking a synthesised approach could be the answer. Michael Liss and Ralf Wagner at GENEART examine the potential of Tailor-Made Proteins  
view
download pdf
RNA purification has always been a struggle for low-throughput laboratories due to the lack of automated platforms. In Technological Expression, Carola Shade at QIAGEN GmbH inspects a selection of brand new, innovative methods that can help to streamline the process  
view
download pdf
In Increasing 15d-PGJ2: a Novel Drug Target, Professor Ernst Wülfert at Hunter-Fleming Ltd believes the production of 15d-PGJ2 should be increased as it boasts several unique properties, despite not currently being a primary target for drug discovery and development  
view
download pdf
Consistent progress is being made in the development of sensitive and efficient assays to swiftly measure the binding of compounds. In Right on Target, Marion de Decker at Cisbio explores recent advances in what is a key element of the drug discovery process  
view
download pdf
bullet
BioDevelopment and Regulatory
Testing is one of the most costly and time-consuming aspects of a drug’s development cycle, but arguably also the most important. In Minimising Immunological Risk, Markus Wulf and Peter Trinder of Thymed GmbH evaluate the crucial parameters in the clinical and preclinical development process of vaccines, drugs and biotherapeutics  
view
download pdf
Inhalation toxicology is establishing its predominance as a method for administering an increasing range of therapies, yet the risks involved cannot be ignored and continuous development is imperative in testing systems and protocols. Paul Smith and Richard Crowley at Covance provide us with A Dose of Inspiration  
view
download pdf
In Making Your Mark, independent consultant Ray Briggs and John Allinson at Veeda Clinical Research attempt to clear up how conflicting definitions of biomarkers, together with discrepancy between the technologies available, have augmented misunderstandings in the past  
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Biologics Day

On 20. July 2018, Phenomenex and SCIEX will co-host a full day of seminars, providing solutions for Biologics. The series of mini-seminars presented by technical experts from both companies, will cover methods for characterisation and QC testing, troubleshooting and new trends in analysis for this industry.  
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

Industry Events

DIA 2018 Global Annual Meeting

24-28 June 2018, Boston, MA

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe. Designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need to do your job every day, your attendance will accelerate your growth and your organization's performance in the development ecosystem.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement